
Insight Molecular Diagnostics fell 72.2% from $6.70 to $1.86, behind the S&P 500's +11.2%. Its worst day was Mar 30 (−28.4%), and its low came Nov 16 at $1.86.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Insight Molecular Diagnostics closed at its highest level of the year, 11.9% above where the year started.
+7.1% · S&P 500 −0.7%
Insight Molecular Diagnostics Inc., (NASDAQ:IMDX), ("iMDx" or the "Company"), today announced that it has entered into definitive agreements with certain institutional investors for the purchase and sale…
Story events cover the past 12 months · Times ET
−22.7% · S&P 500 0.0%
Insight Molecular Diagnostics shares fell 17.8%, while the S&P 500 rose 0.1%.
−17.8% · S&P 500 +0.1%
EPS of $-0.27 missed the $-0.24 estimate on $1.1M revenue (est. $285,000.00).
−13.4% · S&P 500 −1.7%
Insight Molecular Diagnostics shares rose 20.3%, while the S&P 500 rose 1.2%.
+20.3% · S&P 500 +1.2%
Insight Molecular Diagnostics shares rose 25.1%, while the S&P 500 fell 0.4%.
+25.1%, on 2M shares, the year's heaviest volume · S&P 500 −0.4%
EPS of $-0.28 missed the $-0.26 estimate on $32,000.00 revenue (est. $227,500.00).
+25.9% · S&P 500 +0.8%
Insight Molecular Diagnostics shares fell 20.0%, while the S&P 500 fell 2.6%.
−20.0% · S&P 500 −2.6%
EPS of $-0.23 beat the $-0.23 estimate on $239,000.00 revenue (est. $437,500.00).
−7.1% · S&P 500 −0.3%
Insight Molecular Diagnostics shares fell 18.9%, while the S&P 500 fell 0.7%.
−18.9% · S&P 500 −0.7%
Where it ended: a close of $1.86 on Nov 16, 2026. Up next: Q3 2026 earnings on Nov 16, 2026 (EPS est. $-0.22, revenue est. $244,280.00).
Nothing in the past 12 months.
All IMDX dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IMDX and SPY from Benzinga historical bars. Not investment advice.